Whole-genome sequencing (WGS) of cancers is becoming an accepted component of oncological care, and NHS England is currently rolling out WGS for all children with cancer. This approach was piloted during the 100,000 genomes (100K) project. Here we share the experience of the East of England ...
Patient choice consent for whole genome sequencing (WGS) through the Genomic Medicine Service in England covers consent to diagnostic testing and an invitation to the National Genomic Research Library (NGRL). Little is known about what consent conversations for WGS look like in practice. We audio-...
The 100000 Genomes Project: bringing whole genome sequencing to the NHS In partnership with NHS England, Genomics England's ambitious plans to embed genomic medicine into routine patient care are well underway. Clare Turnbull and colleagues discuss its progressMany disorders we encounter in clinical me...
Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing Sci Translat Med, 4 (2012) 148ra116 Google Scholar [5] R. Zarrilli, A. Di Popolo, M. Bagattini, M. Giannouli, D. Martino, M. Barchitta, et al. Clonal spread and patient risk factors...
Genetic testing for cancer predisposition has been curtailed by the cost of sequencing, and testing has been restricted by eligibility criteria. As the cost of sequencing decreases, the question of expanding multi-gene cancer panels to a broader populati
The Genomics England 100000 Genomes Project was initiated in 2013 to establish the use of whole genome sequencing in the NHS and drive change within NHS services to adopt this technology.Fig 1 Potential applications of genomics in medicineThe UK has long been at the forefront of discovery in ...
Whole genome sequencing (WGS) is being used in diagnostic testing for certain clinical indications within the NHS Genomic Medicine Service (GMS) in England. Letter writing is an integral part of delivering results. However, no national guidelines for writing results from WGS exist. This multi-...
It informs that the firm will be chaired by John Chisholm. It also mentions that Chisholm has stated that the firm will create a dataset of whole genome sequences after matching with clinic datasets.HawkesNigelEBSCO_AspBmj British Medical Journal...